Showing 1 - 3 results of 3 for search 'Ann D Bass', query time: 0.03s Refine Results
  1. 1
    The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives

    The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives by Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve

    Published 2022-08-01
    Get full text
    Article
  2. 2
    Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

    Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial by Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj

    Published 2021-04-01
    Get full text
    Article
  3. 3
    Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

    Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings by Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, Elisabeth G. Celius, Jérôme de Seze, Dionisio Dela Cruz, Mario Habek, Jong-Mi Lee, Volker Limmroth, Sven G. Meuth, Celia Oreja-Guevara, Patricia Pagnotta, Cindy Vos, Tjalf Ziemssen, Darren P. Baker, Bart Van Wijmeersch

    Published 2019-03-01
    Get full text
    Article

Search Tools: